secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007864
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023
--------------------------------------------------------------------------------

- R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).
- Cash, equivalents and securities $330.4M as of Dec 31, 2022; expected runway through 2025.
- Phase 1 MAD trial of DT-216 for Friedreich Ataxia ongoing; initial data expected mid-2023, final by year-end.
- IND submission for DT-168 (FECD) planned H2 2023; DM1 program targeting IND in 2024.
- No revenue reported; net loss driven by R&D investment in clinical and preclinical pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/0000950170-23-007864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/dsgn-20230314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer